Johnson & Johnson has reinvested in the microbiome health management app developer, which has now secured $48m in total.
US-based health management app developer DayTwo has received $31m in a series B round featuring healthcare group Johnson & Johnson.
Ofek Ventures and venture capital fund aMoon co-led the round, which was filled out by VC firm Seventure Partners.
Founded in 2015, DayTwo provides an app that is designed to help users manage diet-related illnesses such as type 2 diabetes. It measures a user’s glucose levels and leverages machine learning technology to provide personalised meal suggestions based on their unique gut microbe composition.
The series B proceeds will be used for an expansion in the US as well as the development of additional products and services intended to help patients suffering with metabolic and gastrointestinal conditions. DayTwo has now raised $48m in funding altogether, it said.
Johnson & Johnson’s corporate venturing unit, Johnson & Johnson Innovation – JJDC, had backed DayTwo’s $12m series A round in 2017 alongside medical research firm Mayo Clinic, Seventure Partners’ Health for Life Capital fund, DayTwo co-founder Marius Nacht and undisclosed private investors.
Lihi Segal, founder and chief executive of DayTwo, said: “This deep and broad foundation, coupled with this financing, enables DayTwo to address the large and pressing clinical need to bring food-as-medicine to market for people with type 2 diabetes in the United States.”